問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD933IC00001
Completed

2018-12-01 - 2026-03-31

Phase I

Recruiting8

ICD-10C34

Malignant neoplasm of bronchus and lung

ICD-9162.8

Malignant neoplasm of other parts of bronchus or lung

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Jen-Yu Hung Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator James Chih-Hsin Yang Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator Chien-Chung Lin Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator Yung-Hung Luo Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

1 Recruiting

Audit

None

Principal Investigator 吳銘芳 Division of General Internal Medicine

Co-Principal Investigator

  • 王耀東 Division of General Internal Medicine
  • 曹世明 Division of General Internal Medicine
  • 吳子卿 Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator kang-Yun LEE Division of Thoracic Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

10 Recruiting

Audit

CRO

Principal Investigator Cheng-Ta Yang Division of Hematology & Oncology
Linkou Chang Gung Medical Foundation

Taiwan National PI

楊政達

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

4 Recruiting

Audit

None

Principal Investigator Jen-Yu Hung 未分科

Co-Principal Investigator

Audit

CRO

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    50 participants

  • Global

    200 participants